- Home
- INBX vs VSTM Comparison
INBX vs VSTM Comparison
Compare INBX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- VSTM
- Stock Information
- Founded
- INBX 2010
- VSTM 2010
- Country
- INBX United States
- VSTM United States
- Employees
- INBX N/A
- VSTM N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- VSTM Health Care
- Exchange
- INBX Nasdaq
- VSTM Nasdaq
- Market Cap
- INBX 218.9M
- VSTM 239.9M
- IPO Year
- INBX 2020
- VSTM 2012
- Fundamental
- Price
- INBX $14.19
- VSTM $5.39
- Analyst Decision
- INBX Hold
- VSTM Strong Buy
- Analyst Count
- INBX 1
- VSTM 8
- Target Price
- INBX N/A
- VSTM $12.43
- AVG Volume (30 Days)
- INBX 80.6K
- VSTM 2.4M
- Earning Date
- INBX 11-14-2024
- VSTM 03-13-2025
- Dividend Yield
- INBX N/A
- VSTM N/A
- EPS Growth
- INBX N/A
- VSTM N/A
- EPS
- INBX 119.38
- VSTM N/A
- Revenue
- INBX $1,568,000.00
- VSTM $10,000,000.00
- Revenue This Year
- INBX N/A
- VSTM N/A
- Revenue Next Year
- INBX N/A
- VSTM $117.91
- P/E Ratio
- INBX $0.11
- VSTM N/A
- Revenue Growth
- INBX 19.24
- VSTM N/A
- 52 Week Low
- INBX $10.80
- VSTM $2.10
- 52 Week High
- INBX $18.95
- VSTM $14.22
- Technical
- Relative Strength Index (RSI)
- INBX 47.10
- VSTM 53.22
- Support Level
- INBX $12.51
- VSTM $5.08
- Resistance Level
- INBX $14.86
- VSTM $6.02
- Average True Range (ATR)
- INBX 1.05
- VSTM 0.68
- MACD
- INBX -0.14
- VSTM -0.06
- Stochastic Oscillator
- INBX 38.89
- VSTM 50.79
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.